查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1842401

生技藥品製造市場規模、佔有率和趨勢分析報告：按製造模式、形態、適應症、地區和細分市場預測，2025 年至 2033 年

Biologics Manufacturing Market Size, Share & Trends Analysis Report By Mode Of Manufacturing (Contract, In-House), By Modality, By Disease Indication, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

生技藥品製造市場摘要

預計 2024 年全球生技藥品製造市場價值將達到 334.8 億美元，到 2033 年將達到 1,406.2 億美元，2025 年至 2033 年的複合年成長率為 17.0%。

這一成長主要得益於生物製藥需求的不斷成長、生技藥品生產能力的不斷擴大以及細胞和基因治療製造技術的進步。

慢性病負擔加重

推動全球生技藥品製造業擴張的主要因素之一是糖尿病、癌症、自體免疫疾病和心血管疾病等慢性疾病的發生率不斷上升。由於傳統治療方法往往不足，生物來源的生技藥品製造為這些複雜疾病提供了針對性且有效的治療選擇。需要長期專科治療的患者數量不斷增加，推動了對新型生技藥品製造的需求，促使生產商提高產能並投資於最尖端科技。

此外，慢性病負擔日益加重，使獲得高品質生技藥品生產成為全球醫療保健系統面臨的首要挑戰。為了改善患者預後並降低與慢性病管理相關的長期治療成本，政府和私人醫療保健機構正日益支持生技藥品生產的開發和商業化。未來幾年，市場和監管部門對生技藥品生產的關注預計將支持其產能穩定擴張和技術突破。

對新型標靶治療的需求不斷成長

對創新標靶治療的需求日益成長，推動著生技藥品製造市場的發展。標靶生技藥品，包括單株抗體、抗體藥物複合體以及細胞和基因療法，與傳統藥物療法不同，其特異性靶向疾病的分子病因。這些療法對於癌症、自體免疫疾病和罕見遺傳疾病等疾病極具吸引力，因為它們的精準性可以提高療效並減少副作用。製藥和生物技術公司正在大力投資研發管線，將新的標靶生技藥品推向市場。

主要市場的監管機構正在同步建立有利的核准途徑，以支持突破性生技藥品的臨床應用。此外，標靶治療的成功也加劇了產業競爭，迫使生產者擴大產能、採用尖端生物加工技術並建立策略聯盟。這些進步顯著加速了生技藥品製造業的成長，各公司正努力滿足全球對新型患者特異性療法日益成長的需求。

生技藥品製造的全球市場細分

該報告預測了收益成長，並分析了 2021 年至 2033 年期間每個細分市場的最新趨勢。在本報告中，Grand View Research 根據製造模式、方式、疾病適應症和地區對全球生技藥品製造市場進行了細分。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章市場變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 補貼市場展望
  • 市場趨勢與展望
  • 市場動態
    • 市場促進因素的影響分析
    • 市場限制的影響分析
  • 商業環境分析
    • PESTLE分析
    • 波特五力分析

第4章 按製造模式分類的業務分析

  • 製造模式細分儀表板
  • 全球生技藥品製造市場的波動
  • 2021-2033 年全球生技藥品製造市場規模及趨勢分析（依製造模式）
  • 契約製造
  • 內部製造

第5章 按模式進行業務分析

  • 模態細分儀表板
  • 全球生技藥品製造市場波動分析
  • 全球生技藥品製造市場規模與趨勢分析（按方式，2021-2033 年）
  • 單株抗體（mAb）
  • 生物相似藥和重組蛋白
  • 疫苗（重組/mRNA/病毒）
  • 細胞和基因治療
  • 基於RNA的療法
  • 其他

第6章 業務分析

  • 指示細分儀表板
  • 全球生技藥品製造市場的波動
  • 全球生技藥品製造市場規模與趨勢分析（按適應症，2021-2033 年）
  • 腫瘤學
  • 自體免疫疾病
  • 感染疾病
  • 神經系統疾病
  • 心血管疾病
  • 其他適應症

第7章生技藥品製造市場：區域估計與趨勢分析

  • 區域儀表板
  • 2021-2033年市場規模、預測與趨勢分析
  • 北美洲
    • 2021-2033年北美生技藥品製造市場
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 2021-2033年歐洲生技藥品製造市場
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 2021-2033年亞太地區生技藥品製造市場
    • 日本
    • 中國
    • 印度
    • 新加坡
    • 澳洲
    • 泰國
    • 韓國
  • 拉丁美洲
    • 拉丁美洲生技藥品製造市場（2021-2033）
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 中東和非洲生技藥品製造市場（2021-2033）
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭態勢

  • 公司分類
  • 戰略地圖
  • 2024年企業市場分析
  • 公司簡介/上市公司
    • Novartis AG
    • Pfizer Inc
    • Amgen Inc
    • Novo Nordisk A/S
    • AbbVie Inc.
    • Johnson &Johnson（Johnson &Johnson Services, Inc.）
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • F. Hoffmann La-Roche Ltd.
    • Wuxi Biologics
    • FUJIFILM Holdings Corporation（FUJIFILM Diosynth Biotechnologies）
    • Boehringer Ingelheim International GmbH
    • Lonza
    • Samsung Biologics
Product Code: GVR-4-68040-743-9

Biologics Manufacturing Market Summary

The global biologics manufacturing market size was estimated at USD 33.48 billion in 2024 and is projected to reach USD 140.62 billion by 2033, growing at a CAGR of 17.0% from 2025 to 2033. This growth is primarily driven by increasing demand for biopharmaceuticals, expansion of biologics production capacities, and advancements in cell and gene therapy manufacturing technologies.

Rising burden of chronic disease

One of the main factors expanding the global biologics manufacturing industry is the rising incidence of chronic illnesses such as diabetes, cancer, autoimmune diseases, and cardiovascular conditions. Biologic therapies from living organisms provide targeted and efficient treatment options for these complex conditions, as conventional treatments frequently prove insufficient. The need for novel biologic medications has increased due to the growing number of patients needing long-term, specialized care, which stimulates producers to increase their production capacity and invest in cutting-edge technologies.

Furthermore, access to high-quality biologic therapies is becoming a top priority for healthcare systems worldwide due to the growing burden of chronic diseases. To enhance patient outcomes and lower the long-term treatment expenses related to managing chronic illnesses, governments and private healthcare providers are increasingly supporting the development and commercialization of biologics. Over the years, the market and regulatory emphasis on biologics production is anticipated to support steady expansion in manufacturing capacity and technological breakthroughs.

Growing Demand for Novel and Targeted Therapies

The rising need for innovative and focused treatments propels the biologics manufacturing market. Targeted biologics, including monoclonal antibodies, antibody-drug conjugates, and cell and gene therapies, differ from conventional medications in that they specifically target the molecular causes of illnesses. These treatments are very appealing for diseases such as cancer, autoimmune disorders, and rare genetic diseases because of their precision, which increases treatment efficacy and reduces side effects. Pharmaceutical and biotechnology companies are making significant investments in research pipelines to launch new targeted biologics.

Regulatory bodies in important markets concurrently establish favorable pathways for their approval to support the adoption of breakthrough biologics in clinical practice. Targeted therapy success has also increased industry competition, forcing producers to increase production capacity, embrace cutting-edge bioprocessing technologies, and form strategic alliances. As businesses work to satisfy the growing demand for novel, patient-specific treatments worldwide, these advancements are greatly accelerating the growth of the biologics manufacturing sector.

Global Biologics Manufacturing Market Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global biologics manufacturing market on the basis of mode of manufacturing, modality, disease indication, and region.

  • Mode of Manufacturing Outlook (Revenue, USD Million, 2021 - 2033)
  • Contract Manufacturing
  • In-house manufacturing
  • Modality Outlook (Revenue, USD Million, 2021 - 2033)
  • Monoclonal Antibodies (mAbs)
  • Biosimilar & Recombinant Proteins
  • Vaccines (recombinant/mRNA/Viral)
  • Cell & Gene Therapies
  • RNA-based Therapeutics
  • Others
  • Disease Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Oncology
  • Autoimmune Disorders
  • Infectious Diseases
  • Neurological Disorders
  • Cardiovascular Disorders
  • Other Disease Indications
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Mode
    • 1.2.2. Modality
    • 1.2.3. Disease Indication
  • 1.3. Information analysis
  • 1.4. Market formulation & data visualization
  • 1.5. Data validation & publishing
  • 1.6. Information Procurement
    • 1.6.1. Primary Research
  • 1.7. Information or Data Analysis
  • 1.8. Market Formulation & Validation
  • 1.9. Market Model
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Impact Analysis
      • 3.3.1.1. Rising burden of chronic disease
      • 3.3.1.2. Growing Demand for Novel and Targeted Therapies
    • 3.3.2. Market Restraint Impact Analysis
      • 3.3.2.1. High Manufacturing Costs and Capital Intensity
      • 3.3.2.2. Complex Regulatory and Quality Compliance
  • 3.4. Business Environment Analysis
    • 3.4.1. PESTLE Analysis
    • 3.4.2. PORTER'S Five Forces Analysis

Chapter 4. Mode Business Analysis

  • 4.1. Mode Segment Dashboard
  • 4.2. Global Biologics Manufacturing Market Mode, Movement Analysis
  • 4.3. Global Biologics Manufacturing Market Size & Trend Analysis, by Mode, 2021 to 2033 (USD Million)
  • 4.4. Contract Manufacturing
    • 4.4.1. Global contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.5. In-house manufacturing
    • 4.5.1. Global In-house manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. Modality Business Analysis

  • 5.1. Modality Segment Dashboard
  • 5.2. Global Biologics Manufacturing Market Modality, Movement Analysis
  • 5.3. Global Biologics Manufacturing Market Size & Trend Analysis, by Modality, 2021 to 2033 (USD Million)
  • 5.4. Monoclonal Antibodies (mAbs)
    • 5.4.1. Global monoclonal antibodies (mAbs) market estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.5. Biosimilar & Recombinant Proteins
    • 5.5.1. Global biosimilar & recombinant proteins market estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.6. Vaccines (recombinant/mRNA/Viral)
    • 5.6.1. Global vaccines (recombinant/mRNA/Viral) market estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.7. Cell & Gene Therapies
    • 5.7.1. Global cell & gene therapies market estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.8. RNA-based Therapeutics
    • 5.8.1. Global RNA-based therapeutics market estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.9. Others
    • 5.9.1. Global others market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. Disease Indication Business Analysis

  • 6.1. Disease Indication Segment Dashboard
  • 6.2. Global Biologics Manufacturing Market Disease Indication, Movement Analysis
  • 6.3. Global Biologics Manufacturing Market Size & Trend Analysis, by Disease Indication, 2021 to 2033 (USD Million)
  • 6.4. Oncology
    • 6.4.1. Global Oncology market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.5. Autoimmune Disorders
    • 6.5.1. Global autoimmune disorders market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.6. Infectious Diseases
    • 6.6.1. Global infectious diseases market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.7. Neurological Disorders
    • 6.7.1. Global neurological disorders market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.8. Cardiovascular Disorders
    • 6.8.1. Global cardiovascular disorders market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.9. Others Disease Indications
    • 6.9.1. Global other disease indications market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. Biologics Manufacturing Market: Regional Estimates and Trend Analysis, by Product, Mode, & Disease Indication,

  • 7.1. Regional Dashboard
  • 7.2. Market Size & Forecasts and Trend Analysis, 2021 to 2033
  • 7.3. North America
    • 7.3.1. North America biologics manufacturing market, 2021 - 2033 (USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Target Disease Prevalence
      • 7.3.2.3. Competitive Scenario
      • 7.3.2.4. Regulatory Framework
      • 7.3.2.5. U.S. biologics manufacturing market, 2021 - 2033 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Target Disease Prevalence
      • 7.3.3.3. Competitive Scenario
      • 7.3.3.4. Regulatory Framework
      • 7.3.3.5. Canada biologics manufacturing market, 2021 - 2033 (USD Million)
    • 7.3.4. Mexico
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Target Disease Prevalence
      • 7.3.4.3. Competitive Scenario
      • 7.3.4.4. Regulatory Framework
      • 7.3.4.5. Mexico biologics manufacturing market, 2021 - 2033 (USD Million)
  • 7.4. Europe
    • 7.4.1. Europe biologics manufacturing market, 2021 - 2033 (USD Million)
    • 7.4.2. UK
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Target Disease Prevalence
      • 7.4.2.3. Competitive Scenario
      • 7.4.2.4. Regulatory Framework
      • 7.4.2.5. UK biologics manufacturing market, 2021 - 2033 (USD Million)
    • 7.4.3. Germany
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Target Disease Prevalence
      • 7.4.3.3. Competitive Scenario
      • 7.4.3.4. Regulatory Framework
      • 7.4.3.5. Germany biologics manufacturing market, 2021 - 2033 (USD Million)
    • 7.4.4. France
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Target Disease Prevalence
      • 7.4.4.3. Competitive Scenario
      • 7.4.4.4. Regulatory Framework
      • 7.4.4.5. France biologics manufacturing market, 2021 - 2033 (USD Million)
    • 7.4.5. Italy
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Target Disease Prevalence
      • 7.4.5.3. Competitive Scenario
      • 7.4.5.4. Regulatory Framework
      • 7.4.5.5. Italy biologics manufacturing market, 2021 - 2033 (USD Million)
    • 7.4.6. Spain
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Target Disease Prevalence
      • 7.4.6.3. Competitive Scenario
      • 7.4.6.4. Regulatory Framework
      • 7.4.6.5. Spain biologics manufacturing market, 2021 - 2033 (USD Million)
    • 7.4.7. Denmark
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Target Disease Prevalence
      • 7.4.7.3. Competitive Scenario
      • 7.4.7.4. Regulatory Framework
      • 7.4.7.5. Denmark biologics manufacturing market, 2021 - 2033 (USD Million)
    • 7.4.8. Sweden
      • 7.4.8.1. Key Country Dynamics
      • 7.4.8.2. Target Disease Prevalence
      • 7.4.8.3. Competitive Scenario
      • 7.4.8.4. Regulatory Framework
      • 7.4.8.5. Sweden biologics manufacturing market, 2021 - 2033 (USD Million)
    • 7.4.9. Norway
      • 7.4.9.1. Key Country Dynamics
      • 7.4.9.2. Target Disease Prevalence
      • 7.4.9.3. Competitive Scenario
      • 7.4.9.4. Regulatory Framework
      • 7.4.9.5. Norway biologics manufacturing market, 2021 - 2033 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Asia Pacific biologics manufacturing market, 2021 - 2033 (USD Million)
    • 7.5.2. Japan
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Target Disease Prevalence
      • 7.5.2.3. Competitive Scenario
      • 7.5.2.4. Regulatory Framework
      • 7.5.2.5. Japan biologics manufacturing market, 2021 - 2033 (USD Million)
    • 7.5.3. China
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Target Disease Prevalence
      • 7.5.3.3. Competitive Scenario
      • 7.5.3.4. Regulatory Framework
      • 7.5.3.5. China biologics manufacturing market, 2021 - 2033 (USD Million)
    • 7.5.4. India
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Target Disease Prevalence
      • 7.5.4.3. Competitive Scenario
      • 7.5.4.4. Regulatory Framework
      • 7.5.4.5. India biologics manufacturing market, 2021 - 2033 (USD Million)
    • 7.5.5. Singapore
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Target Disease Prevalence
      • 7.5.5.3. Competitive Scenario
      • 7.5.5.4. Regulatory Framework
      • 7.5.5.5. Singapore biologics manufacturing market, 2021 - 2033 (USD Million)
    • 7.5.6. Australia
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Target Disease Prevalence
      • 7.5.6.3. Competitive Scenario
      • 7.5.6.4. Regulatory Framework
      • 7.5.6.5. Australia biologics manufacturing market, 2021 - 2033 (USD Million)
    • 7.5.7. Thailand
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Target Disease Prevalence
      • 7.5.7.3. Competitive Scenario
      • 7.5.7.4. Regulatory Framework
      • 7.5.7.5. Thailand biologics manufacturing market, 2021 - 2033 (USD Million)
    • 7.5.8. South Korea
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Target Disease Prevalence
      • 7.5.8.3. Competitive Scenario
      • 7.5.8.4. Regulatory Framework
      • 7.5.8.5. South Korea biologics manufacturing market, 2021 - 2033 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Latin America biologics manufacturing market, 2021 - 2033 (USD Million)
    • 7.6.2. Brazil
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Target Disease Prevalence
      • 7.6.2.3. Competitive Scenario
      • 7.6.2.4. Regulatory Framework
      • 7.6.2.5. Brazil biologics manufacturing market, 2021 - 2033 (USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Target Disease Prevalence
      • 7.6.3.3. Competitive Scenario
      • 7.6.3.4. Regulatory Framework
      • 7.6.3.5. Argentina biologics manufacturing market, 2021 - 2033 (USD Million)
  • 7.7. MEA
    • 7.7.1. MEA biologics manufacturing market, 2021 - 2033 (USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Target Disease Prevalence
      • 7.7.2.3. Competitive Scenario
      • 7.7.2.4. Regulatory Framework
      • 7.7.2.5. South Africa biologics manufacturing market, 2021 - 2033 (USD Million)
    • 7.7.3. Saudi Arabia
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Target Disease Prevalence
      • 7.7.3.3. Competitive Scenario
      • 7.7.3.4. Regulatory Framework
      • 7.7.3.5. Saudi Arabia biologics manufacturing market, 2021 - 2033 (USD Million)
    • 7.7.4. UAE
      • 7.7.4.1. Key Country Dynamics
      • 7.7.4.2. Target Disease Prevalence
      • 7.7.4.3. Competitive Scenario
      • 7.7.4.4. Regulatory Framework
      • 7.7.4.5. UAE biologics manufacturing market, 2021 - 2033 (USD Million)
    • 7.7.5. Kuwait
      • 7.7.5.1. Key Country Dynamics
      • 7.7.5.2. Target Disease Prevalence
      • 7.7.5.3. Competitive Scenario
      • 7.7.5.4. Regulatory Framework
      • 7.7.5.5. Kuwait biologics manufacturing market, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Position Analysis, 2024
  • 8.4. Company Profiles/Listing
    • 8.4.1. Novartis AG
      • 8.4.1.1. Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Strategic Initiatives
    • 8.4.2. Pfizer Inc
      • 8.4.2.1. Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Strategic Initiatives
    • 8.4.3. Amgen Inc
      • 8.4.3.1. Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Strategic Initiatives
    • 8.4.4. Novo Nordisk A/S
      • 8.4.4.1. Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Strategic Initiatives
    • 8.4.5. AbbVie Inc.
      • 8.4.5.1. Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Strategic Initiatives
    • 8.4.6. Johnson & Johnson (Johnson & Johnson Services, Inc.)
      • 8.4.6.1. Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Strategic Initiatives
    • 8.4.7. Bristol-Myers Squibb Company
      • 8.4.7.1. Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Strategic Initiatives
    • 8.4.8. Eli Lilly and Company
      • 8.4.8.1. Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Strategic Initiatives
    • 8.4.9. F. Hoffmann La-Roche Ltd.
      • 8.4.9.1. Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Strategic Initiatives
    • 8.4.10. Wuxi Biologics
      • 8.4.10.1. Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Strategic Initiatives
    • 8.4.11. FUJIFILM Holdings Corporation (FUJIFILM Diosynth Biotechnologies)
      • 8.4.11.1. Overview
      • 8.4.11.2. Financial Performance
      • 8.4.11.3. Product Benchmarking
      • 8.4.11.4. Strategic Initiatives
    • 8.4.12. Boehringer Ingelheim International GmbH
      • 8.4.12.1. Overview
      • 8.4.12.2. Financial Performance
      • 8.4.12.3. Product Benchmarking
      • 8.4.12.4. Strategic Initiatives
    • 8.4.13. Lonza
      • 8.4.13.1. Overview
      • 8.4.13.2. Financial Performance
      • 8.4.13.3. Product Benchmarking
      • 8.4.13.4. Strategic Initiatives
    • 8.4.14. Samsung Biologics
      • 8.4.14.1. Overview
      • 8.4.14.2. Financial Performance
      • 8.4.14.3. Product Benchmarking
      • 8.4.14.4. Strategic Initiatives

List of Tables

  • Table 1. List of Secondary Sources
  • Table 2. List of Abbreviations
  • Table 3. Global Biologics Manufacturing Market, by Mode, 2021 - 2033 (USD Million)
  • Table 4. Global Biologics Manufacturing Market, by Modality, 2021 - 2033 (USD Million)
  • Table 5. Global Biologics Manufacturing Market, by Disease Indication, 2021 - 2033 (USD Million)
  • Table 6. Global Biologics Manufacturing Market, by Region, 2021 - 2033 (USD Million)
  • Table 7. North America Biologics Manufacturing Market, by Country, 2021 - 2033 (USD Million)
  • Table 8. North America Biologics Manufacturing Market, by Mode, 2021 - 2033 (USD Million)
  • Table 9. North America Biologics Manufacturing Market, by Modality, 2021 - 2033 (USD Million)
  • Table 10. North America Biologics Manufacturing Market, by Disease Indication, 2021 - 2033 (USD Million)
  • Table 11. U.S. Biologics Manufacturing Market, by Product, 2021 - 2033 (USD Million)
  • Table 12. U.S. Biologics Manufacturing Market, by Mode, 2021 - 2033 (USD Million)
  • Table 13. U.S. Biologics Manufacturing Market, by Modality, 2021 - 2033 (USD Million)
  • Table 14. U.S. Biologics Manufacturing Market, by Disease Indication, 2021 - 2033 (USD Million)
  • Table 15. Canada Biologics Manufacturing Market, by Product, 2021 - 2033 (USD Million)
  • Table 16. Canada Biologics Manufacturing Market, by Mode, 2021 - 2033 (USD Million)
  • Table 17. Canada Biologics Manufacturing Market, by Modality, 2021 - 2033 (USD Million)
  • Table 18. Canada Biologics Manufacturing Market, by Disease Indication, 2021 - 2033 (USD Million)
  • Table 19. Mexico Biologics Manufacturing Market, by Product, 2021 - 2033 (USD Million)
  • Table 20. Mexico Biologics Manufacturing Market, by Mode, 2021 - 2033 (USD Million)
  • Table 21. Mexico Biologics Manufacturing Market, by Modality, 2021 - 2033 (USD Million)
  • Table 22. Mexico Biologics Manufacturing Market, by Disease Indication, 2021 - 2033 (USD Million)
  • Table 23. Europe Biologics Manufacturing Market, by Country, 2021 - 2033 (USD Million)
  • Table 24. Europe Biologics Manufacturing Market, by Product, 2021 - 2033 (USD Million)
  • Table 25. Europe Biologics Manufacturing Market, by Mode, 2021 - 2033 (USD Million)
  • Table 26. Europe Biologics Manufacturing Market, by Modality, 2021 - 2033 (USD Million)
  • Table 27. Europe Biologics Manufacturing Market, by Disease Indication, 2021 - 2033 (USD Million)
  • Table 28. Germany Biologics Manufacturing Market, by Product, 2021 - 2033 (USD Million)
  • Table 29. Germany Biologics Manufacturing Market, by Mode, 2021 - 2033 (USD Million)
  • Table 30. Germany Biologics Manufacturing Market, by Modality, 2021 - 2033 (USD Million)
  • Table 31. Germany Biologics Manufacturing Market, by Disease Indication, 2021 - 2033 (USD Million)
  • Table 32. UK Biologics Manufacturing Market, by Product, 2021 - 2033 (USD Million)
  • Table 33. UK Biologics Manufacturing Market, by Mode, 2021 - 2033 (USD Million)
  • Table 34. UK Biologics Manufacturing Market, by Modality, 2021 - 2033 (USD Million)
  • Table 35. UK Biologics Manufacturing Market, by Disease Indication, 2021 - 2033 (USD Million)
  • Table 36. France Biologics Manufacturing Market, by Product, 2021 - 2033 (USD Million)
  • Table 37. France Biologics Manufacturing Market, by Mode, 2021 - 2033 (USD Million)
  • Table 38. France Biologics Manufacturing Market, by Modality, 2021 - 2033 (USD Million)
  • Table 39. France Biologics Manufacturing Market, by Disease Indication, 2021 - 2033 (USD Million)
  • Table 40. Italy Biologics Manufacturing Market, by Product, 2021 - 2033 (USD Million)
  • Table 41. Italy Biologics Manufacturing Market, by Mode, 2021 - 2033 (USD Million)
  • Table 42. Italy Biologics Manufacturing Market, by Modality, 2021 - 2033 (USD Million)
  • Table 43. Italy Biologics Manufacturing Market, by Disease Indication, 2021 - 2033 (USD Million)
  • Table 44. Spain Biologics Manufacturing Market, by Product, 2021 - 2033 (USD Million)
  • Table 45. Spain Biologics Manufacturing Market, by Mode, 2021 - 2033 (USD Million)
  • Table 46. Spain Biologics Manufacturing Market, by Modality, 2021 - 2033 (USD Million)
  • Table 47. Spain Biologics Manufacturing Market, by Disease Indication, 2021 - 2033 (USD Million)
  • Table 48. Denmark Biologics Manufacturing Market, by Product, 2021 - 2033 (USD Million)
  • Table 49. Denmark Biologics Manufacturing Market, by Mode, 2021 - 2033 (USD Million)
  • Table 50. Denmark Biologics Manufacturing Market, by Modality, 2021 - 2033 (USD Million)
  • Table 51. Denmark Biologics Manufacturing Market, by Disease Indication, 2021 - 2033 (USD Million)
  • Table 52. Norway Biologics Manufacturing Market, by Product, 2021 - 2033 (USD Million)
  • Table 53. Norway Biologics Manufacturing Market, by Mode, 2021 - 2033 (USD Million)
  • Table 54. Norway Biologics Manufacturing Market, by Modality, 2021 - 2033 (USD Million)
  • Table 55. Norway Biologics Manufacturing Market, by Disease Indication, 2021 - 2033 (USD Million)
  • Table 56. Sweden Biologics Manufacturing Market, by Product, 2021 - 2033 (USD Million)
  • Table 57. Sweden Biologics Manufacturing Market, by Mode, 2021 - 2033 (USD Million)
  • Table 58. Sweden Biologics Manufacturing Market, by Modality, 2021 - 2033 (USD Million)
  • Table 59. Sweden Biologics Manufacturing Market, by Disease Indication, 2021 - 2033 (USD Million)
  • Table 60. Asia Pacific Biologics Manufacturing Market, by Country, 2021 - 2033 (USD Million)
  • Table 61. Asia Pacific Biologics Manufacturing Market, by Product, 2021 - 2033 (USD Million)
  • Table 62. Asia Pacific Biologics Manufacturing Market, by Mode, 2021 - 2033 (USD Million)
  • Table 63. Asia Pacific Biologics Manufacturing Market, by Modality, 2021 - 2033 (USD Million)
  • Table 64. Asia Pacific Biologics Manufacturing Market, by Disease Indication, 2021 - 2033 (USD Million)
  • Table 65. China Biologics Manufacturing Market, by Product, 2021 - 2033 (USD Million)
  • Table 66. China Biologics Manufacturing Market, by Mode, 2021 - 2033 (USD Million)
  • Table 67. China Biologics Manufacturing Market, by Modality, 2021 - 2033 (USD Million)
  • Table 68. China Biologics Manufacturing Market, by Disease Indication, 2021 - 2033 (USD Million)
  • Table 69. Japan Biologics Manufacturing Market, by Product, 2021 - 2033 (USD Million)
  • Table 70. Japan Biologics Manufacturing Market, by Mode, 2021 - 2033 (USD Million)
  • Table 71. Japan Biologics Manufacturing Market, by Modality, 2021 - 2033 (USD Million)
  • Table 72. Japan Biologics Manufacturing Market, by Disease Indication, 2021 - 2033 (USD Million)
  • Table 73. India Biologics Manufacturing Market, by Product, 2021 - 2033 (USD Million)
  • Table 74. India Biologics Manufacturing Market, by Mode, 2021 - 2033 (USD Million)
  • Table 75. India Biologics Manufacturing Market, by Modality, 2021 - 2033 (USD Million)
  • Table 76. India Biologics Manufacturing Market, by Disease Indication, 2021 - 2033 (USD Million)
  • Table 77. South Korea Biologics Manufacturing Market, by Product, 2021 - 2033 (USD Million)
  • Table 78. South Korea Biologics Manufacturing Market, by Mode, 2021 - 2033 (USD Million)
  • Table 79. South Korea Biologics Manufacturing Market, by Modality, 2021 - 2033 (USD Million)
  • Table 80. South Korea Biologics Manufacturing Market, by Disease Indication, 2021 - 2033 (USD Million)
  • Table 81. Australia Biologics Manufacturing Market, by Product, 2021 - 2033 (USD Million)
  • Table 82. Australia Biologics Manufacturing Market, by Mode, 2021 - 2033 (USD Million)
  • Table 83. Australia Biologics Manufacturing Market, by Modality, 2021 - 2033 (USD Million)
  • Table 84. Australia Biologics Manufacturing Market, by Disease Indication, 2021 - 2033 (USD Million)
  • Table 85. Thailand Biologics Manufacturing Market, by Product, 2021 - 2033 (USD Million)
  • Table 86. Thailand Biologics Manufacturing Market, by Mode, 2021 - 2033 (USD Million)
  • Table 87. Thailand Biologics Manufacturing Market, by Modality, 2021 - 2033 (USD Million)
  • Table 88. Thailand Biologics Manufacturing Market, by Disease Indication, 2021 - 2033 (USD Million)
  • Table 89. Latin America Biologics Manufacturing Market, by Country, 2021 - 2033 (USD Million)
  • Table 90. Latin America Biologics Manufacturing Market, by Product, 2021 - 2033 (USD Million)
  • Table 91. Latin America Biologics Manufacturing Market, by Mode, 2021 - 2033 (USD Million)
  • Table 92. Latin America Biologics Manufacturing Market, by Modality, 2021 - 2033 (USD Million)
  • Table 93. Latin America Biologics Manufacturing Market, by Disease Indication, 2021 - 2033 (USD Million)
  • Table 94. Brazil Biologics Manufacturing Market, by Product, 2021 - 2033 (USD Million)
  • Table 95. Brazil Biologics Manufacturing Market, by Mode, 2021 - 2033 (USD Million)
  • Table 96. Brazil Biologics Manufacturing Market, by Modality, 2021 - 2033 (USD Million)
  • Table 97. Brazil Biologics Manufacturing Market, by Disease Indication, 2021 - 2033 (USD Million)
  • Table 98. Argentina Biologics Manufacturing Market, by Product, 2021 - 2033 (USD Million)
  • Table 99. Argentina Biologics Manufacturing Market, by Mode, 2021 - 2033 (USD Million)
  • Table 100. Argentina Biologics Manufacturing Market, by Modality, 2021 - 2033 (USD Million)
  • Table 101. Argentina Biologics Manufacturing Market, by Disease Indication, 2021 - 2033 (USD Million)
  • Table 102. Middle East and Africa Biologics Manufacturing Market, by Country, 2021 - 2033 (USD Million)
  • Table 103. Middle East and Africa Biologics Manufacturing Market, by Product, 2021 - 2033 (USD Million)
  • Table 104. Middle East and Africa Biologics Manufacturing Market, by Mode, 2021 - 2033 (USD Million)
  • Table 105. Middle East and Africa Biologics Manufacturing Market, by Modality, 2021 - 2033 (USD Million)
  • Table 106. Middle East and Africa Biologics Manufacturing Market, by Disease Indication, 2021 - 2033 (USD Million)
  • Table 107. South Africa Biologics Manufacturing Market, by Product, 2021 - 2033 (USD Million)
  • Table 108. South Africa Biologics Manufacturing Market, by Mode, 2021 - 2033 (USD Million)
  • Table 109. South Africa Biologics Manufacturing Market, by Modality, 2021 - 2033 (USD Million)
  • Table 110. South Africa Biologics Manufacturing Market, by Disease Indication, 2021 - 2033 (USD Million)
  • Table 111. Saudi Arabia Biologics Manufacturing Market, by Product, 2021 - 2033 (USD Million)
  • Table 112. Saudi Arabia Biologics Manufacturing Market, by Mode, 2021 - 2033 (USD Million)
  • Table 113. Saudi Arabia Biologics Manufacturing Market, by Modality, 2021 - 2033 (USD Million)
  • Table 114. Saudi Arabia Biologics Manufacturing Market, by Disease Indication, 2021 - 2033 (USD Million)
  • Table 115. UAE Biologics Manufacturing Market, by Product, 2021 - 2033 (USD Million)
  • Table 116. UAE Biologics Manufacturing Market, by Mode, 2021 - 2033 (USD Million)
  • Table 117. UAE Biologics Manufacturing Market, by Modality, 2021 - 2033 (USD Million)
  • Table 118. UAE Biologics Manufacturing Market, by Disease Indication, 2021 - 2033 (USD Million)
  • Table 119. Kuwait Biologics Manufacturing Market, by Product, 2021 - 2033 (USD Million)
  • Table 120. Kuwait Biologics Manufacturing Market, by Mode, 2021 - 2033 (USD Million)
  • Table 121. Kuwait Biologics Manufacturing Market, by Modality, 2021 - 2033 (USD Million)
  • Table 122. Kuwait Biologics Manufacturing Market, by Disease Indication, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Biologics manufacturing market segmentation
  • Fig. 2 Data analysis models
  • Fig. 3 Market formulation and validation
  • Fig. 4 Data validation & publishing
  • Fig. 5 Market research process
  • Fig. 6 Information procurement
  • Fig. 7 Primary research
  • Fig. 8 Value-chain-based sizing & forecasting
  • Fig. 9 QFD modelling for market share assessment
  • Fig. 10 Market formulation & validation
  • Fig. 11 Commodity flow analysis
  • Fig. 12 Market outlook
  • Fig. 13 Segment snapshot-1
  • Fig. 14 Competitive landscape snapshot
  • Fig. 15 Market trends & outlook
  • Fig. 16 PESTEL analysis
  • Fig. 17 Porter's five forces analysis
  • Fig. 18 Biologics manufacturing market: Mode outlook key takeaways
  • Fig. 19 Biologics manufacturing market: Mode movement analysis
  • Fig. 20 Contract manufacturing market, 2021 - 2033 (USD Million)
  • Fig. 21 In-house manufacturing market, 2021 - 2033 (USD Million)
  • Fig. 22 Biologics manufacturing market: Modality outlook key takeaways
  • Fig. 23 Biologics manufacturing market: Modality movement analysis
  • Fig. 24 Monoclonal antibodies (mAbs)market, 2021 - 2033 (USD Million)
  • Fig. 25 Biosimilar & recombinant proteins market, 2021 - 2033 (USD Million)
  • Fig. 26 Vaccines (recombinant/mRNA/Viral) market, 2021 - 2033 (USD Million)
  • Fig. 27 Cell & gene therapies market, 2021 - 2033 (USD Million)
  • Fig. 28 RNA-based therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 29 Others market, 2021 - 2033 (USD Million)
  • Fig. 30 Biologics manufacturing market: Disease Indication outlook key takeaways
  • Fig. 31 Biologics manufacturing market: Disease Indication movement analysis
  • Fig. 32 Oncology market, 2021 - 2033 (USD Million)
  • Fig. 33 Autoimmune disorders market, 2021 - 2033 (USD Million)
  • Fig. 34 Infectious diseases market, 2021 - 2033 (USD Million)
  • Fig. 35 Neurological disorders market, 2021 - 2033 (USD Million)
  • Fig. 36 Cardiovascular disorders market, 2021 - 2033 (USD Million)
  • Fig. 37 Other disease indications market, 2021 - 2033 (USD Million)
  • Fig. 38 Regional marketplace outlook, 2024 & 2033 (USD Million)
  • Fig. 39 Regional marketplace: Key takeaways
  • Fig. 40 North America biologics manufacturing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 41 Key country dynamics
  • Fig. 42 U.S. biologics manufacturing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 43 Key country dynamics
  • Fig. 44 Canada biologics manufacturing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 45 Key country dynamics
  • Fig. 46 Mexico biologics manufacturing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 47 Europe biologics manufacturing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 Germany biologics manufacturing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 50 Key country dynamics
  • Fig. 51 UK biologics manufacturing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 52 Key country dynamics
  • Fig. 53 France biologics manufacturing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 54 Key country dynamics
  • Fig. 55 Italy biologics manufacturing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 56 Key country dynamics
  • Fig. 57 Spain biologics manufacturing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 58 Key country dynamics
  • Fig. 59 Denmark biologics manufacturing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 60 Key country dynamics
  • Fig. 61 Sweden biologics manufacturing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 62 Key country dynamics
  • Fig. 63 Norway biologics manufacturing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 64 Asia Pacific biologics manufacturing market estimates and forecast, 2021 - 2033, (USD Million)
  • Fig. 65 Key country dynamics
  • Fig. 66 Japan biologics manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 67 Key country dynamics
  • Fig. 68 China biologics manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 69 Key country dynamics
  • Fig. 70 India biologics manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 71 Key country dynamics
  • Fig. 72 South Korea biologics manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 73 Key country dynamics
  • Fig. 74 Australia biologics manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 75 Key country dynamics
  • Fig. 76 Thailand biologics manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 77 Latin America biologics manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 78 Key country dynamics
  • Fig. 79 Brazil biologics manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 Argentina biologics manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 82 MEA biologics manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 83 Key country dynamics
  • Fig. 84 South Africa biologics manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 85 Key country dynamics
  • Fig. 86 Saudi Arabia biologics manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 87 Key country dynamics
  • Fig. 88 UAE biologics manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 89 Key country dynamics
  • Fig. 90 Kuwait biologics manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 91 Market position analysis
  • Fig. 92 Market participant categorization
  • Fig. 93 Strategic framework